Протизапальна терапія атеросклеротичних серцево-судинних захворювань

M. І. Lutay, Oleksandr M. Lomakovskyi, Ilona P Golikova et al. · Ukrainian Journal of Cardiology · 2025

In primary prevention studies, inflammation and hyperlipidemia predicted future cardiovascular events with similar accuracy. These initial epidemiological data eventually led to clinical trials that demonstrated that anti-inflammatory agents can significantly reduce the incidence of cardiovascular events without altering blood lipids. As lipid-lowering therapy has become more effective, inflammation has emerged as an important source of residual cardiovascular risk. These data are important in selecting additional therapies to reduce cardiovascular risk because they suggest that anti-inflammatory therapies are not yet fully utilized in clinical care and that focusing solely on lowering atherogenic lipids is unlikely to eliminate all vascular risk. This issue has gained more relevance since low-dose colchicine became the first anti-inflammatory agent approved by the US Food and Drug Administration for use as an adjunctive therapy to reduce the risk of recurrent myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Recent evidence suggests that inflammatory mechanisms have not yet been fully exploited for the benefit of the patient.

Cited by 0 works. doi:10.31928/2664-4479-2025.5.4653 Open-access PDF

Authors

References